Results 111 to 120 of about 17,302 (216)

Real‐World Survival Outcomes of Venetoclax Combination Therapies in Acute Myeloid Leukemia: Impact of Minimal Residual Disease Status and Antifungal Prophylaxis

open access: yesHematological Oncology, Volume 44, Issue 6, November 2026.
ABSTRACT In recent years the addition of the oral BCL2 inhibitor venetoclax to hypomethylating agents (HMAs) has emerged as the standard‐of‐care for patients with acute myeloid leukemia (AML) who are not fit for intensive chemotherapy, significantly improving survival and quality‐of‐life.
Mariarita Sciumè   +9 more
wiley   +1 more source

The Efferocytosis‐Driven Macrophage Polarization: A Concerto in the Tumor Immunosuppressive Microenvironment

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Efferocytosis is a key process for macrophages to clear apoptotic cells, which undergoes the “ Find Me” chemotaxis signal stage, the “eat me” phagocytosis recognition stage and the “digest me” digestion stage in turn. During the aforementioned three stages, various signaling molecules released by apoptotic cells can promote the phenotypic polarization ...
Qiuping Chen   +3 more
wiley   +1 more source

Self-assemblies of azacitidine prodrugs: a promising strategy of treatment for myelodysplastic syndromes

open access: yes, 2021
International audience5-Azacitidine, a cytidine analogue and a hypomethylating agent, is a staple drug being in the treatment of myelodysplastic syndromes [1].
El-Makhour, Yolla   +4 more
core   +1 more source

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

open access: yes, 2017
Purpose Azacitidine is standard, first-line therapy in higher-risk myelodysplastic syndromes (MDS). Whether azacitidine-based combinations with lenalidomide or vorinostat produce superior overall response rates (ORRs) to azacitidine is not known ...
Olatoyosi Odenike   +45 more
core   +1 more source

Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang   +4 more
wiley   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 21, Page 6261-6290, November 2026.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Synergistic apoptosis induction in myelodysplastic syndrome cells by azacitidine and PIM-2 inhibitors via nuclear factor-kappa B pathway inhibition

open access: yesBMC Cancer
Background We aimed to characterise the molecular effects of treating myelodysplastic syndrome (MDS) cells with the DNA methyltransferase inhibitor azacitidine and an PIM-2 inhibitor, focusing on their potential synergistic effects.
Yixuan Guo   +6 more
doaj   +1 more source

Case Report: Use of mirvetuximab soravtansine in a patient with platinum-resistant ovarian cancer and concomitant PARP-inhibitor-related myelodysplastic syndrome

open access: yesFrontiers in Oncology
Response rates in platinum-resistant ovarian cancer remain low (16–30%) and decline with subsequent lines of therapy. Mirvetuximab soravtansine (MIRV), an antibody–drug conjugate targeting folate receptor alpha (FRα), has demonstrated clinically ...
Sophonie Shilonite Njonou Noujiep   +7 more
doaj   +1 more source

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3‐ITD–Positive AML

open access: yesCancer Science, Volume 117, Issue 11, Page 3108-3120, November 2026.
ABSTRACT Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3‐ITD–positive AML.
Yuichiro Semba   +21 more
wiley   +1 more source

Olutasidenib Alone or in Combination With Azacitidine as a Bridge to Transplant in Relapsed/Refractory mIDH1 AML

open access: yes
European Journal of Haematology, Volume 117, Issue 6, Page 1671-1675, December 2026.
Shira N. Dinner   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy